Clopidogrel outperforms aspirin in reducing thrombotic and bleeding risk in chronic maintenance phase post-PCI with DES: 10-year HOST-EXAM findings

Evolocumab reduces first MACE in high-risk patients without established atherosclerosis: Subgroup analysis from the VESALIUS-CV trial

The phase 3 SCOUT-HCM trial shows mavacamten significantly improves LVOT obstruction in adolescents with HCM

The Ez-PAVE trial: Intensive LDL-C targeting reduces 3-year CV events in ASCVD patients

FFRangio demonstrates non-inferiority to pressure wire based physiologic assessment in intermediate coronary lesions: Results from the ALL-RISE randomized trial